文献速递腹部介入MR

nVR模型:预测肝细胞癌经动脉化疗栓塞后LI-RADS治疗反应无活性病灶的复发

The nVR model: prediction of LI-RADS treatment response nonviable recurrence of hepatocellular carcinoma after primary transarterial chemoembolization.
PubMed 文献 · Abdom Radiol (NY) · 2025-04-11

这项多中心回顾性研究纳入五个中心2015年2月至2022年10月首次接受TACE的肝细胞癌患者,构建基于MRI特征和临床特征的模型,预测首次随访(1-2个月)评估为LR-TR无活性病灶的早期复发(<12个月)。非光滑边缘(OR 4.69)和瘤周T2WI/DWI高信号(OR 6.12)为独立危险因素,nVR模型训练队列AUC 0.759、验证队列AUC 0.765,按Youden指数分层后两组无复发生存率显著不同。

要点

  • 首次TACE后1-2个月评估为LR-TR无活性的病灶仍有早期复发风险,需结合MRI特征预判。
  • 非光滑边缘(OR 4.69)和瘤周T2WI/DWI高信号(OR 6.12)是无活性病灶早期复发的独立危险因素。
  • 基于上述两个影像特征的nVR模型训练队列AUC 0.759、验证队列AUC 0.765,可按Youden指数分层。

核心结论

  • 基于非光滑边缘和瘤周T2WI/DWI高信号两个影像特征构建的nVR模型,在预测TACE后LR-TR无活性病灶早期复发方面显示出相对可靠的效能。

研究设计与样本

  • 多中心回顾性研究,纳入五个中心2015年2月至2022年10月首次接受TACE的连续肝细胞癌患者,并纳入一项已完成临床试验(NCT03113955)的患者进行回顾性分析。

关键影像表现/征象

  • 评估了19个基线影像特征和6个首次随访影像特征,用于首次TACE后影像评估分类为LR-TR无活性的病灶。
  • 非光滑边缘为早期复发的独立危险因素(OR 4.69;95% CI 1.91, 11.56;P = 0.001)。
  • 瘤周T2加权成像或扩散加权成像高信号为早期复发的独立危险因素(OR 6.12;95% CI 2.53, 14.80;P < 0.001)。

诊断标准与关键数值

  • nVR模型由非光滑边缘和瘤周T2WI/DWI高信号两个特征构建,训练队列AUC 0.759(95% CI 0.734, 0.784),验证队列AUC 0.765(95% CI 0.632, 0.898)。
  • 按Youden指数将患者分为高风险组和低风险组,训练队列两组无复发生存率差异显著(P < 0.001),验证队列亦显著(P = 0.009)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study aims to build a prediction model based on MRI features and clinical characteristics for early tumor recurrence (< 12 months) in lesions which evaluated as LR-TR nonviable at first follow up (1-2 months) after transaterial chemoembolization (TACE).

METHODS: This multicenter retrospective study included consecutive patients with hepatocellular carcinoma (HCC) who underwent initial TACE from five centers between February 2015 and October 2022. Additionally, patients from a completed clinical trial (NCT03113955) were also included for this retrospective analysis. Nineteen baseline imaging features and six first follow-up imaging features were evaluated for lesions classified as LR-TR nonviable at the first post-TACE imaging assessment. A predictive model integrating clinical and MRI features for early recurrence of LR-TR nonviable lesions was developed with logistic regression analyses and validated on a 5-fold cross-validation. The model's performance was further validated by analyzing relapse-free survival (RFS) using Kaplan-Meier curves.

RESULTS: Non-smooth margin (OR: 4.69; 95% CI: 1.91, 11.56; P = 0.001) and peritumoral hyperintensity on T2-weighted imaging or diffusion-weighted imaging (OR: 6.12; 95% CI: 2.53, 14.80; P < 0.001) were identified as independent risk factors for early recurrence of LR-TR nonviable lesions. The non-Viable Recurrence (nVR) model, developed using these two features, achieved area under the receiver operating characteristic curve of 0.759 (0.734, 0.784) in the training cohort and 0.765 (0.632, 0.898) in the validation cohort. Patients were stratified into high-risk and low-risk groups based on the Youden index, with RFS significantly differing between these groups in both the training (P < 0.001) and validation cohorts (P = 0.009).

CONCLUSION: Based on two radiologic features, the nVR model has demonstrated relatively reliable efficacy in predicting early post-TACE recurrence.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Zhang S, Wang W, Zhang X, et al. The nVR model: prediction of LI-RADS treatment response nonviable recurrence of hepatocellular carcinoma after primary transarterial chemoembolization. Abdom Radiol (NY). 2025. PMID: 40214697. doi:10.1007/s00261-025-04924-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。